- Home
- GXAI vs KPRX Comparison
GXAI vs KPRX Comparison
Compare GXAI & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- KPRX
- Stock Information
- Founded
- GXAI 2021
- KPRX 1998
- Country
- GXAI United States
- KPRX United States
- Employees
- GXAI N/A
- KPRX N/A
- Industry
- GXAI
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GXAI
- KPRX Health Care
- Exchange
- GXAI Nasdaq
- KPRX Nasdaq
- Market Cap
- GXAI 9.7M
- KPRX 8.6M
- IPO Year
- GXAI 2023
- KPRX N/A
- Fundamental
- Price
- GXAI $1.25
- KPRX $2.92
- Analyst Decision
- GXAI
- KPRX Strong Buy
- Analyst Count
- GXAI 0
- KPRX 1
- Target Price
- GXAI N/A
- KPRX $10.00
- AVG Volume (30 Days)
- GXAI 159.4K
- KPRX 62.0K
- Earning Date
- GXAI 08-12-2025
- KPRX 08-08-2025
- Dividend Yield
- GXAI N/A
- KPRX N/A
- EPS Growth
- GXAI N/A
- KPRX N/A
- EPS
- GXAI N/A
- KPRX N/A
- Revenue
- GXAI $27,740.00
- KPRX $20,000.00
- Revenue This Year
- GXAI N/A
- KPRX N/A
- Revenue Next Year
- GXAI N/A
- KPRX N/A
- P/E Ratio
- GXAI N/A
- KPRX N/A
- Revenue Growth
- GXAI 9987.27
- KPRX N/A
- 52 Week Low
- GXAI $1.00
- KPRX $2.51
- 52 Week High
- GXAI $7.50
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- GXAI 41.89
- KPRX 46.55
- Support Level
- GXAI $1.30
- KPRX $2.68
- Resistance Level
- GXAI $1.65
- KPRX $2.96
- Average True Range (ATR)
- GXAI 0.10
- KPRX 0.17
- MACD
- GXAI -0.02
- KPRX 0.00
- Stochastic Oscillator
- GXAI 4.77
- KPRX 47.06
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.